Efficacy of continuous i.v. infusion of recombinant human vascular endothelial growth inhibitor in combination with chemotherapy in patients with advanced lung cancer.

OBJECTIVE

This study aimed to observe the efficacy of continuous i.v. infusion of Recombinant Human Vascular Endothelial Growth Inhibitor (rhVEGI) in combination with chemotherapy in patients with advanced lung cancer (ALC).

METHODS

Eighty-six patients with ALC treated at our hospital between November 2018 and May 2020 were divided into two groups of 43 patients each according to a random number table. The control group (CG) was treated with routine chemotherapy, and the experimental group (EG) was treated with continuous i.v. Infusion of rhVEGI plus chemotherapy. The two groups were compared in terms of clinical efficacy, toxic side effects, immune function (T-lymphocyte subsets CD4, CD8, CD4/CD8), changes in neovascular parameters (serum bFGF, VEGF, MMP-9), quality of life, and survival rate within 6 months between two groups.

RESULTS

The response rate (81.40%) was higher in the EG (60.47%) than in the CG (P<0.05). After treatment, CD4 and CD4/CD8 increased in both groups, while CD8, serum bFGF, VEGF, and MMP-9 levels decreased, and the improvement in the EG was better than that in the CG (P<0.05). Three months after treatment, all quality of life scores increased in both groups, and were higher in the EG than in the CG (P<0.05). The mortality rate (32.56%) was lower in the EG (32.56%) than in the CG (67.44%) (P<0.05).

CONCLUSION

Continuous i.v. infusion of rhVEGI combined with chemotherapy can effectively enhance clinical treatment efficacy, inhibit tumor cell growth, improve immune function, reduce mortality, and improve quality of life without increasing adverse effects in patients with ALC.